Fig. 3From: Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life studyDirect medical, direct non-medical and indirect costs for all patients, patients with lower disability (BI 91–100), and patient with higher disability (BI < 91) (2020, €)Back to article page